EGFR
The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma
Seminars in Diagnostic Pathology. 2006 Feb;23(1):35-43. [Link] Davidson B, Risberg B, Berner A, Bedrossian CW, Reich R. Department of Pathology, Norwegian Radium Hospital-National Hospital, University of Oslo, Oslo, Norway. ben.davidson@radiumhospitalet.no Abstract Recent improvements in immunohistochemistry panels used for differentiating ovarian serous carcinoma/primary peritoneal carcinoma (OC/PPC) from diffuse malignant peritoneal mesothelioma (DMPM) have resulted in improved…
Read MoreDrug targets to pro-angiogenetic factors with special reference to primary peritoneal mesothelioma
Endocrine, Metabolic & Immune Disorders Drug Targets. 2006 Sep;6(3):271-7. [Link] Ranieri G, Ruggieri E, Falco G, Zizzo N, Mattioli E, Zito AF, Patruno R, Gasparini G. Department of Experimental Oncology, National Cancer Institute of Bari, Bari, Italy. giroran@tiscalinet.it Abstract Angiogenesis is necessary for growth and the spread of human tumors. Animal studies also suggest that…
Read MoreThe Extracellular Domain of p185(c-neu) Induces Density-Dependent Inhibition of Cell Growth in Malignant Mesothelioma Cells and Reduces Growth of Mesothelioma In Vivo
DNA and Cell Biology. Sep 2006, Vol. 25, No. 9: 530-540 [Link] Yoneda T, Kumagai T, Nagatomo I, Furukawa M, Yamane H, Hoshino S, Mori M, Takeda Y, Horai T, Nishida S, Watanabe D, Kijima T, Yoshida M, Osaki T, Tachibana I, Greene MI, Kawase I. Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka…
Read MoreEGFR overexpression in malignant pleural mesothelioma An immunohistochemical and molecular study with clinico-pathological correlations
Lung Cancer. 2005 Dec 26; [Epub ahead of print]. [Link] Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V, Alloisio M, Rizzi A, Bosari S, Roncalli M. Molecular Genetics Laboratory, IRCCS Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milano, Italy. Abstract The epidermal growth factor…
Read MoreMesothelioma: advances in chemotherapy
Revue des Maladies Respiratoire. 2005 Dec;22(6-C2):49-54. [Link] Jacoulet P. Service de Pneumologie, CHU, Besancon, France. Abstract Chemotherapy is often the only treatment possible for locally advanced or metastatic mesothelioma. This paper recalls which drugs might have therapeutic benefits in this condition and reviews recent studies of chemotherapy or targeted therapy. If the patient cannot be…
Read MoreInterleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma
Anti-Cancer Drugs. 17(1):1-12, January 2006. [Link] Grande, Carlos a; Firvida, Jose Luis b; Navas, Victor c; Casal, Joaquin a Abstract Interleukin-2 (IL-2) is a lymphokine produced by T cells whose main function is to stimulate the growth and cytotoxic response of activated T lymphocytes. It has been used to stimulate the immune system for the…
Read MorePerspective on the development of new agents in thoracic cancers
Lung Cancer. Volume 50, Supplement 1 , 2005, Pages S27-S28. Available online 12 November 2005. [Link] L. Einhorn Indiana University Cancer Center, 535 Barnhill Drive Room 473, Indianapolis, IN 46202-5289, USA Abstract The development of several targeted agents that play a critical role in the growth and survival of carcinomas has paved the way for…
Read MoreReceptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma
The Journal of Thoracic and Cardiovascular Surgery 2005 Aug;130 (2):393-400 Philip A. Rascoe, MDa, Xiaobo Cao, MDb, Jonathan C. Daniel, MDa, Steven D. Miller, MDa, W. Roy Smythe, MDb,* a Department of Thoracic and Cardiovascular Surgery, Section of Thoracic Molecular Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Tex b Scott and White…
Read MoreTherapeutic Targeting of Multiple Signaling Pathways in Malignant Pleural Mesothelioma
Oncology. July 13, 2005;68:500-510. [Link] Toru Mukoharaa-c, Gabriel Civielloa, Bruce E. Johnsona-c, Pasi A. Jännea-c aLowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute; Departments of Medicine, bBrigham and Women’s Hospital and cHarvard Medical School, Boston, Mass., USA Abstract The majority of malignant pleural mesotheliomas (MPMs) aberrantly express the epidermal growth factor…
Read MoreThe selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro
The Journal of Thorscic Cardiovascular Surgery. 2005 May;129 (5):1010-7. [Link] Cole GW Jr, Alleva AM, Reddy RM, Maxhimer JB, Zuo J, Schrump DS, Nguyen DM. Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute/NIH, 10 Center Drive, Bethesda, MD 20892, USA Abstract Objective: Malignant pleural mesothelioma is notoriously refractory to aggressive…
Read More